Oryzon Genomics S.A. (0RDB.L)
| Previous close | 1.9980 |
| Open | 0.0000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | 2,518 |
| Market cap | 719,784 |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0880 |
| Earnings date | 11 Jul 2024 - 16 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireORYZON to Provide Corporate Progress Updates at Several Events in May
Bio-Equity Europe 2024Asebio Investor Day 2024RSC Hot Topics: Covalent Drug DiscoveryForo Medcap BME 2024 MADRID, Spain and CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events in May. Oryzon will attend Bio
Globe NewswireORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2024
Finalizing full data analysis from vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder (BPD) Company planning to request an End-of-Phase II meeting with the FDA to discuss plans for a registrational Phase III trial in BPDStrengthening the IP position in CNS with formal notices of intention to grant in the EU and Korea for patent application covering the use of vafidemstat to treat aggression and social withdrawalContinues to recruit patients in FRIDA trial with iadademstat i
- GlobeNewswire
ORYZON Secures Another Important Patent for its Lead CNS Asset, Vafidemstat
Has received “Intention to Grant” from the European Patent Office For the treatment of aggression and social withdrawal MADRID, Spain and CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the European Patent Office (EPO) has issued an “intention to grant” communication for Oryzon’s European
